ArticleBMC surgery2020
Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study.
Article in BMC surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Association between vedolizumab and postoperative complications in IBD: a systematic review and meta-analysis.International journal of colorectal disease · 2021Pooled it
- Biologics Before Surgery Are Not Associated With Complications After Surgery for IBD: A National Surgery Quality Improvement Program IBD Collaborative Causal Inference Analysis.Diseases of the colon and rectum · 2026Article
- A rare case of ulcerative colitis relapse in a diverted colon after rectal cancer surgery: efficacy of carotegrast methyl.Clinical journal of gastroenterology · 2026Article
- The Rectal Stump During and After Subtotal Colectomy for Ulcerative Colitis: A Narrative Review of Surgical Strategies, Medical Management Options, and Cancer Surveillance Recommendations.Journal of clinical medicine · 2026Review
- Comparative Risk of Complications Following Intestinal Surgery After Infliximab, Vedolizumab, or Ustekinumab Treatment: Systematic Review & Meta-Analysis.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Impact of biologics on stoma creation and reversal in Crohn's disease: a retrospective analysis from 2007 to 2021.Techniques in coloproctology · 2025Observational
- Extensive Colitis and Smoking Are Associated With Postoperative Complications Within 30 Days of Ileal Pouch-Anal Anastomosis.Inflammatory bowel diseases · 2024Article
- Surgical Outcomes in 62 Patients with Ulcerative Colitis: A Retrospective, Single-Center Study from Poland.Medical science monitor : international medical journal of experimental and clinical research · 2023Article
- Perioperative Assessment and Optimization in Major Colorectal Surgery: Medication Management.Clinics in colon and rectal surgery · 2023Review
- Preoperative Biologics Exposure Predisposes Ulcerative Colitis Patients to a Distinct Delayed Postoperative Ileus Syndrome After Colectomy.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- The Effect of Anti-Tumor Necrosis Factor-Alpha Therapy within 12 Weeks Prior to Surgery on Postoperative Complications in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2022Review
- Elective and Emergent Surgery in the Ulcerative Colitis Patient.Clinics in colon and rectal surgery · 2022Review
- Staging Pouch Surgery in Ulcerative Colitis in the Biological Era.Clinics in colon and rectal surgery · 2022Review
- Acute Severe Colitis: The Need for Joint Management between Gastroenterologists and Surgeons.Clinics in colon and rectal surgery · 2022Review
- Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu.Journal of clinical medicine · 2021Article
- Influence of nutritional status in the postoperative period of patients with inflammatory bowel disease.World journal of gastrointestinal pharmacology and therapeutics · 2021Review
- Hypoalbuminaemia, Not Biologic Exposure, Is Associated with Postoperative Complications in Crohn's Disease Patients Undergoing Ileocolic Resection.Journal of Crohn's & colitis · 2021Article
- Exploring the Relationship between Biologics and Postoperative Surgical Morbidity in Ulcerative Colitis: A Review.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough biologic agents have revolutionized the medical management of severe ulcerative colitis (UC), there is considerable controversy regarding adverse effects of vedolizumab on surgical outcomes. We evaluated 30-day postoperative morbidity in UC patients undergoing abdominal colectomy (AC) treated with vedolizumab before surgery.
methodsFrom 2007 to 2017, 285 patients were enrolled in prospectively maintained database evaluating the role of clinical, serologic markers with clinical phenotypes in UC. The patients treated with vedolizumab within 12 weeks of AC was queried, then matched 1:3:3 into 3 preoperative treatment groups based on age, gender and surgical treatment of UC; ileal pouch-anal anastomosis (IPAA) with ileostomy vs total colectomy with end stoma: a) vedolizumab (n = 25); b) anti-tumor necrosis factor (anti-TNF) (n = 74); and c) no biologics (n = 54). Thirty-day postoperative complications among patient groups were compared.
resultsThe 3 patient groups were well-matched in other characteristics including disease duration, disease extent, medication history and preoperative serological data. There were no significant differences in the overall incidence of postoperative complications among patients treated preoperatively with vedolizumab, anti-TNFs, or no biologics (44% vs. 45% vs. 37%; p = 0.67). Although there was no significant difference between patient cohorts in infectious complications (p = 0.20), postoperative ileus (POI) was significantly more common among the vedolizumab group (n = 9; 36%) compared to anti-TNF (n = 12; 16%) or no biologics (n = 5; 9%) (p = 0.01). Multivariable analysis showed that vedolizumab treatment prior to surgery was an independent risk factor for POI (OR: 5.16, 95% CI; 1.71-15.52; p = .004).
conclusionAlthough preoperative vedolizumab exposure did not influence the rate of overall 30-day postoperative complications, vedolizumab tends to increase incidence of POI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.